{
  "id": "mhgap#risk_safety_049d0428",
  "content": "psychosocial interventions in their treatment plan\ny Compared with placebo, baclofen does not increase\nand should only consider medication alone for\nthe number of participants with at least one adverse\nadults with alcohol dependence when psychosocial\nevent at the end of treatment (high certainty) and\ninterventions are not available.\ndoes not increase the number of dropouts due to\nadverse events (high certainty).\nResearch gaps\ny In subgroup analysis for baclofen versus placebo,\ny The majority of the evidence is from high-income\nfor some outcomes (return to any drinking and\ncountries (HICs). Further research is needed in low-\npercentage of days abstinent), baclofen showed\nand middle-income countries (LMICs).\nbetter effectiveness for people with alcohol\ny All RCTs excluded participants with comorbid\ndependence post-detoxification (after management\nsevere mental disorders, but five studies recruited\nof withdrawal syndrome) when compared with\nparticipants under stable doses of antidepressants.\npeople who are using alcohol (non-detoxified), but\nFurther research is required to investigate baclofen’s\nno differences were identified for low/high dosages\nprofile of efficacy and safety among those with\nor duration of treatment. For other outcomes\ncomorbid severe mental disorders.\n(dropouts from treatment), duration of treatment\ny Further evidence is required to conclude whether",
  "metadata": {
    "source": "WHO mhGAP-IG 2023",
    "url": "https://www.who.int/",
    "condition": "General",
    "risk_band": "low",
    "topics": [
      "risk_safety",
      "management"
    ],
    "is_clinical": true,
    "is_advice": false
  },
  "index_text": "General — Risk Safety psychosocial interventions in their treatment plan\ny Compared with placebo, baclofen does not increase\nand should only consider medication alone for\nthe number of participants with at least one adverse\nadults with alcohol dependence when psychosocial\nevent at the end of treatment (high certainty) and\ninterventions are not available.\ndoes not increase the number of dropouts due to\nadverse events (high certainty).\nResearch gaps\ny In subgroup analysis for baclofen versus placebo,\ny The majority of the evidence is from high-income\nfor some outcomes (return to any drinking and\ncountries (HICs). Further research is needed in low-\npercentage of days abstinent), baclofen showed\nand middle-income countries (LMICs).\nbetter effectiveness for people with alcohol\ny All RCTs excluded participants with comorbid\ndependence post-detoxification (after management\nsevere mental disorders, but five studies recruited\nof withdrawal syndrome) when compared with\nparticipants under stable doses of antidepressants.\npeople who are using alcohol (non-detoxified), but\nFurther research is required to investigate baclofen’s\nno differences were identified for low/high dosages\nprofile of efficacy and safety among those with\nor duration of treatment. For other outcomes\ncomorbid severe mental disorders.\n(dropouts from treatment), duration of treatment\ny Further evidence is required to conclude whether Psychosocial interventions in their treatment plan\ny compared with placebo, baclofen does not increase\nand should only consider medication alone for\nthe number of participants with at least one adverse\nadults with alcoho..."
}